Apremilast Axunio: Uses, Dosage & Side Effects

What Is Apremilast Axunio and What Is It Used For?

Apremilast Axunio contains the active substance apremilast, a small-molecule inhibitor that selectively targets phosphodiesterase 4 (PDE4), an intracellular enzyme that plays a central role in the regulation of inflammatory responses. PDE4 is the dominant phosphodiesterase expressed in immune and inflammatory cells, including T cells, monocytes, macrophages, neutrophils, dendritic cells, and keratinocytes. By selectively inhibiting PDE4, apremilast prevents the degradation of cyclic adenosine monophosphate (cAMP), a key intracellular signaling molecule. The resulting increase in cAMP levels leads to a cascade of downstream effects that broadly modulate the inflammatory immune response.

Specifically, elevated cAMP activates protein kinase A (PKA), which in turn phosphorylates transcription factors such as cAMP response element-binding protein (CREB) and activating transcription factor 1 (ATF-1). This activation leads to downregulation of pro-inflammatory mediators including tumor necrosis factor-alpha (TNF-α), interleukin-17 (IL-17), interleukin-23 (IL-23), interferon-gamma (IFN-γ), and other cytokines that drive the pathological immune responses seen in psoriasis, psoriatic arthritis, and Behcet's disease. Simultaneously, apremilast upregulates anti-inflammatory mediators such as interleukin-10 (IL-10), resulting in a net reduction in inflammation without the broad immunosuppression associated with traditional immunosuppressants or biologic therapies.

This unique mechanism of action distinguishes apremilast from other systemic treatments for psoriasis and psoriatic arthritis. Unlike biologic agents that target a single specific cytokine (such as TNF-α inhibitors, IL-17 inhibitors, or IL-23 inhibitors), apremilast works intracellularly to modulate the expression of multiple inflammatory mediators simultaneously. This broader but more nuanced approach to immune modulation contributes to its favorable safety profile while still providing clinically meaningful therapeutic effects.

Approved Indications

Apremilast Axunio is approved for three distinct clinical indications in adults:

• Moderate-to-severe plaque psoriasis: For adult patients who are candidates for systemic therapy, meaning those whose psoriasis is not adequately controlled by topical treatments alone, or who have widespread disease affecting quality of life. In the pivotal ESTEEM 1 and ESTEEM 2 clinical trials, apremilast demonstrated significant improvement in Psoriasis Area and Severity Index (PASI) scores, with approximately 33% of patients achieving PASI 75 (at least 75% improvement) at week 16 compared to approximately 5% with placebo. The clinical benefit was sustained over 52 weeks in patients who responded to treatment.
• Active psoriatic arthritis (PsA): For adult patients who have had an inadequate response or who are intolerant to prior disease-modifying antirheumatic drug (DMARD) therapy. The PALACE 1, 2, and 3 trials demonstrated that apremilast significantly improved signs and symptoms of PsA, including joint tenderness and swelling, physical function, enthesitis, and dactylitis. Approximately 40% of patients achieved ACR20 (American College of Rheumatology 20% improvement criteria) at week 16 compared to approximately 19% with placebo. Apremilast can be used alone or in combination with DMARDs including methotrexate.
• Oral ulcers associated with Behcet's disease: For adult patients for whom other systemic therapies are inappropriate. The BCT-002 trial demonstrated that apremilast significantly reduced the number and pain of oral ulcers, with patients experiencing a statistically significant reduction in the number of oral ulcers and improvement in oral ulcer pain compared to placebo at week 12. This indication addresses a significant unmet medical need, as Behcet's disease oral ulcers can be severely debilitating and were previously lacking approved targeted therapies.

Apremilast was first approved by the U.S. Food and Drug Administration (FDA) in March 2014 for psoriatic arthritis and subsequently for plaque psoriasis in September 2014. The European Medicines Agency (EMA) granted marketing authorization in January 2015. It is now approved in more than 50 countries worldwide. Apremilast Axunio represents a formulation of apremilast that provides the same therapeutic benefits with equivalent bioavailability to the originator product.

What Should You Know Before Taking Apremilast Axunio?

Contraindications

The primary contraindication to Apremilast Axunio is known hypersensitivity (allergy) to apremilast or to any of the excipients listed in the product formulation. Hypersensitivity reactions have been reported in clinical trials and post-marketing surveillance, including cases of angioedema and anaphylaxis. If you develop signs of a severe allergic reaction (such as swelling of the face, lips, tongue, or throat, difficulty breathing, or severe rash), discontinue the medication immediately and seek urgent medical attention.

Apremilast Axunio is also contraindicated during pregnancy. Animal reproductive studies have demonstrated embryotoxicity, including increased post-implantation loss and reduced fetal weight, at doses that are clinically relevant. Women of childbearing potential must use effective contraception during treatment and for at least 28 days after stopping apremilast. A pregnancy test is recommended before initiating treatment.

Warnings and Precautions

Before starting Apremilast Axunio, discuss the following considerations with your healthcare provider:

• Psychiatric disorders: Depression, including suicidal ideation and behavior, has been reported during treatment with apremilast. In clinical trials, depression was reported in approximately 1.3% of patients treated with apremilast compared to 0.4% with placebo. Patients with a history of psychiatric illness, including depression or suicidal behavior, should be carefully assessed before initiating treatment, and ongoing monitoring is recommended. Patients and their caregivers should be advised to report any changes in behavior or mood to the prescribing physician.
• Body weight: Apremilast can cause weight loss. In clinical trials, approximately 12% of patients experienced weight loss of 5-10% of body weight, and approximately 2% experienced weight loss exceeding 10%. Body weight should be monitored regularly during treatment. If unexplained or clinically significant weight loss occurs, the patient should be evaluated, and discontinuation of apremilast should be considered. Patients who are underweight at baseline should have their body weight monitored more frequently.
• Severe renal impairment: In patients with severe kidney impairment (creatinine clearance less than 30 mL/min), the dose of apremilast should be reduced to 30 mg once daily (rather than twice daily). During the initial titration period, only the morning doses should be administered. No dose adjustment is needed for mild or moderate renal impairment.
• Lactose intolerance: Apremilast tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medication.

Pregnancy and Breastfeeding

Apremilast Axunio must not be used during pregnancy. Animal studies have shown embryotoxicity at clinically relevant exposures, including increased post-implantation loss and reductions in fetal weight. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential must use effective contraception during treatment and for at least 28 days after the last dose. Before starting treatment, pregnancy should be excluded with a pregnancy test.

It is not known whether apremilast or its metabolites are excreted in human breast milk. A risk to the breastfed infant cannot be excluded. A decision must be made whether to discontinue breastfeeding or discontinue treatment, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. Women should not breastfeed during treatment with apremilast.

Driving and Operating Machinery

Apremilast has no or negligible influence on the ability to drive and use machines. No studies on the effects on driving ability have been performed. However, some patients may experience dizziness as a side effect. If you experience dizziness while taking apremilast, avoid driving or operating machinery until the symptoms resolve.

How Does Apremilast Axunio Interact with Other Drugs?

Apremilast is primarily metabolized by cytochrome P450 3A4 (CYP3A4), with minor contributions from CYP1A2 and CYP2A6. This metabolic pathway means that substances which strongly induce CYP3A4 enzyme activity can significantly accelerate the breakdown of apremilast, reducing its blood levels and potentially diminishing its therapeutic effectiveness. Understanding these interactions is crucial for ensuring optimal treatment outcomes.

In a pharmacokinetic interaction study, co-administration of apremilast with rifampicin (a potent CYP3A4 inducer) resulted in a 72% decrease in the area under the curve (AUC) and a 43% decrease in peak concentration (Cmax) of apremilast. This degree of reduction is clinically significant and is expected to reduce the efficacy of apremilast substantially. Therefore, co-administration of apremilast with strong CYP3A4 inducers is not recommended.

Conversely, co-administration with ketoconazole (a strong CYP3A4 inhibitor) increased apremilast AUC by approximately 36% and had no meaningful effect on Cmax. This modest increase does not require dose adjustment, indicating that strong CYP3A4 inhibitors do not pose a clinically significant interaction risk.

In clinical pharmacokinetic studies, apremilast did not show clinically significant interactions with methotrexate when the two drugs were co-administered. This is particularly relevant for patients with psoriatic arthritis, where apremilast may be used in combination with methotrexate or other DMARDs. Similarly, apremilast did not affect the pharmacokinetics of oral contraceptives containing ethinylestradiol and norgestimate, confirming that hormonal contraception remains effective during apremilast treatment.

Apremilast is not a clinically relevant inhibitor or inducer of CYP enzymes and is therefore unlikely to affect the metabolism of other medications. Population pharmacokinetic analyses have not identified any clinically significant effects of co-administered medications on apremilast pharmacokinetics, aside from the strong CYP3A4 inducers discussed above. However, as with any prescription medication, patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking to ensure comprehensive safety monitoring.

What Is the Correct Dosage of Apremilast Axunio?

Apremilast Axunio should always be used exactly as prescribed by your doctor. The recommended maintenance dose for all three approved indications (psoriasis, psoriatic arthritis, and Behcet's disease oral ulcers) is 30 mg taken orally twice daily, approximately 12 hours apart. However, treatment must begin with a gradual dose titration over the first 6 days to reduce the incidence and severity of gastrointestinal adverse events, particularly diarrhea and nausea.

Initial Dose Titration Schedule

The mandatory 6-day dose titration schedule is as follows:

An initial titration starter pack is typically available, containing the appropriate tablets for the first two weeks of treatment. The starter pack includes the exact tablets needed for the 6-day titration plus maintenance doses for the remainder of the first two weeks. This helps ensure correct dosing during the critical initial period.

Adults

From Day 6 onwards, the recommended maintenance dose is 30 mg taken twice daily (morning and evening). The tablets should be swallowed whole and can be taken with or without food. There is no clinically meaningful food effect on the absorption of apremilast, giving patients flexibility in when they take their medication relative to meals. Doses should be taken approximately 12 hours apart to maintain consistent blood levels throughout the day.

For psoriasis, treatment response should be assessed at week 16 (approximately 4 months). If no response is observed by week 24, treatment should be reconsidered. For psoriatic arthritis, treatment response is typically evaluated at week 16-24. For Behcet's disease oral ulcers, clinical improvement may be observed within 6 weeks, and the benefit of long-term treatment should be periodically reassessed.

Children and Adolescents

The safety and efficacy of apremilast have not been established in children and adolescents under 18 years of age. No clinical data are available in this age group, and Apremilast Axunio is therefore not recommended for use in pediatric patients. Psoriasis and psoriatic arthritis in children and adolescents may require different treatment approaches, and healthcare providers should consider age-appropriate alternatives.

Elderly Patients

No dose adjustment is required for elderly patients. Clinical trials included patients aged 65 years and older. While no overall differences in safety and efficacy were observed between older and younger patients, greater sensitivity in some older individuals cannot be ruled out. As elderly patients are more likely to have decreased renal function and lower body weight, careful monitoring is advisable. Elderly patients may also be at increased risk of gastrointestinal side effects and weight loss.

Severe Renal Impairment

For patients with severe renal impairment (creatinine clearance less than 30 mL/min, estimated using the Cockcroft-Gault equation), the dose should be reduced to 30 mg once daily. During the initial titration period, only the morning doses in the titration schedule should be taken, skipping the evening doses. No dose adjustment is required for patients with mild or moderate renal impairment.

Missed Dose

If you miss a dose, take it as soon as you remember. If it is close to the time for your next scheduled dose, skip the missed dose and take the next dose at the regular time. Do not take a double dose to make up for a missed dose. Using a daily reminder system (alarm, pill organizer, or mobile phone app) can help maintain adherence to the twice-daily dosing schedule.

Overdose

In the event of overdose, contact your doctor immediately or seek emergency medical attention. Apremilast was studied at a total daily dose of up to 100 mg (50 mg twice daily) in healthy volunteers for 4.5 days without evidence of dose-limiting toxicity. There is no specific antidote for apremilast overdose. In the event of overdose, symptomatic and supportive treatment is recommended. Apremilast is not dialyzable due to its high protein binding (approximately 68%).

What Are the Side Effects of Apremilast Axunio?

Like all medicines, Apremilast Axunio can cause side effects, although not everybody gets them. The side effect profile of apremilast has been well characterized through extensive clinical trial programs (involving more than 4,800 patients across the ESTEEM, PALACE, and BCT studies) and post-marketing surveillance. The majority of adverse reactions are mild to moderate in severity, occur most frequently during the first two weeks of treatment, and tend to resolve with continued use. The mandatory dose titration schedule was specifically developed to reduce the incidence and severity of gastrointestinal side effects.

The following side effects have been reported with apremilast, categorized by frequency:

The gastrointestinal side effects, particularly diarrhea and nausea, deserve special attention because they are the most commonly reported adverse events and the primary reason for treatment discontinuation in clinical trials. In the ESTEEM and PALACE studies, diarrhea occurred in approximately 17-19% of patients receiving apremilast versus 8% with placebo during the first 16 weeks. However, the majority of diarrhea episodes were mild to moderate, occurred during the first two weeks of treatment, and resolved within the first month without medical intervention. Severe diarrhea leading to treatment discontinuation occurred in fewer than 2% of patients.

Weight loss is another important side effect to be aware of. In clinical trials, approximately 12% of patients treated with apremilast experienced weight loss of 5-10% of their body weight, and approximately 2% experienced weight loss exceeding 10% of body weight. While some patients may view modest weight loss favorably, unexplained or excessive weight loss warrants clinical evaluation and potential treatment reassessment, particularly in patients who are already underweight.

How Should You Store Apremilast Axunio?

Proper storage of Apremilast Axunio is essential to maintain the integrity and effectiveness of the medication. The following storage conditions should be observed at all times:

• Temperature: Store below 30°C (86°F). Do not refrigerate or freeze. Room temperature storage is appropriate for most household environments.
• Light protection: Keep the tablets in the original blister packaging or container to protect from light. Exposure to direct sunlight or strong artificial light may affect the stability of the medication.
• Moisture protection: Store in a dry place. Do not store in the bathroom or other areas with high humidity, as moisture can affect tablet integrity.
• Original packaging: Keep the tablets in their original blister packaging until you are ready to take them. This protects against both light and moisture exposure.
• Expiry date: Do not use Apremilast Axunio after the expiry date stated on the blister or carton. The expiry date refers to the last day of that month.
• Child safety: Keep all medications out of the reach and sight of children. Store in a secure location, preferably in a locked cabinet or high shelf.

Do not dispose of medications via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help protect the environment and prevent accidental exposure to others.

What Does Apremilast Axunio Contain?

Each film-coated tablet of Apremilast Axunio contains apremilast as the active substance, in one of three strengths:

• 10 mg tablets: Each film-coated tablet contains 10 mg of apremilast. Used during the initial dose titration period (Days 1-3).
• 20 mg tablets: Each film-coated tablet contains 20 mg of apremilast. Used during the dose titration period (Days 3-5).
• 30 mg tablets: Each film-coated tablet contains 30 mg of apremilast. Used as the maintenance dose from Day 6 onwards (30 mg twice daily).

The other ingredients (excipients) in the tablet core typically include: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The film-coating contains: polyvinyl alcohol, titanium dioxide (E171), macrogol, talc, and iron oxide pigments for color differentiation between tablet strengths.

The different tablet strengths are visually distinguishable by their color and shape to help patients correctly identify the appropriate dose during the titration period. The 10 mg tablets are typically pink, the 20 mg tablets are brown, and the 30 mg tablets are beige. Each tablet is embossed with identifying markings to confirm the strength.